Key Takeaways The phase 2 study of a bemnifosbuvir and ruzasvir regimen for the...
Read More
Fabian Rodas Ochoa, MD, transplant hepatologist and clinical assistant professor of medicine at UT...
Survodutide has an “acceptable safety profile” in patients with metabolic dysfunction-associated steatohepatitis with compensated and decompensated cirrhosis,...
Texas Liver Institute’s Dr. Eric Lawitz and colleagues publish clinical trial results on 2...
Learn a little about the history of liver transplantation and exciting emerging areas in...
Reference: https://www.universityhealth.com/news/university-health-transplant-institute-named-best-liver-transplant-program-in-country
Listen to Dr. Rodas discuss the management of non-alcoholic fatty liver disease in patients...